



Leads to Development opens new offices in London and Lyon

Demand for non-clinical development support drives expansion

Paris (France), 10th October 2010 – Leads To Development (L2D), specialist in the non-clinical development of novel therapeutics, is opening new offices in London (UK) and Lyon (France) just one year after the establishment of the Paris-based firm, as demand for its non-clinical development services continues to increase. L2D is a pioneering business created to manage the non-clinical aspects of development projects, allowing biotech and pharmaceutical companies to bring in expertise as and when needed without having to build additional headcount and infrastructure.

Dr Jonathan Kearsley, founder and director of L2D explained: “We’ve seen substantial demand and uptake of our services across Europe. The UK and France are important markets for us and opening satellite offices in London and Lyon is an important step in L2D’s development. The London office is based at the London Bioscience Innovation Centre and will allow biotech companies in the London, Oxford and Cambridge triangle to have faster and easier access to our expertise. Lyon has also shown itself to be an area of growth with great future potential and having an office at the centre of the Lyonbiopôle (Rhône –Alps) cluster will further enhance our client service offering.”

All non-clinical development activities can be outsourced to L2D which will manage part, or all, of the therapeutic programme from development plan design and writing through to the submission of the clinical trial application. Non-clinical development encompasses all development activities required to be able to submit a clinical trial application, whatever the phase, including preclinical, as well as all the non-clinical aspects of phase I, II and III clinical trials. To complement these activities, L2D also provides business and strategic advice (including due diligence) to investors, biotechs, and pharma.

L2D is the first independent company of its kind specialising in the management of the non-clinical development of therapeutics and will be attending the *BioPartnering Europe* event to be held in London from 10th to 12th October 2010.

-ends-

Dr Jonathan Kearsley
Managing Director
Leads To Development
Registered address
166 Boulevard du Montparnasse,
75014 Paris
France

Tel: +44 (0) 207 183 6415
Tel: + 33 (0) 1 82 28 53 70/ +33 (0) 4 81 91 55 60
Mobile: +33 (0) 689 34 57 32
<http://www.leadstodevelopment.com>

Media contact

Richard Anderson
Richard Anderson PR
T. +44(0)-7973-950376
E. richard@richardandersonpr.com
W. www.richardandersonpr.com

About Leads To Development

Leads To Development (L2D) manages the development of lead compounds for its clients, from *in vivo* proof of concept through to clinical trials. Outsourcing this highly specialised non-clinical phase of drug development to L2D allows investors and R&D companies to reach clinical milestones faster, therefore building company value rapidly and cost-effectively.

L2D designs optimal and customised development plans based on its clients’ scientific and business objectives. Validated plans are then implemented and managed by L2D, through to and including submission of the clinical trial applications.

L2D was created in 2009 and leverages the considerable scientific, project management, business and regulatory expertise of its founders, particularly in the areas of oncology, neurology and diabetes. The founders have a proven international track record in the biotech R&D arena, and significant experience in the development of small molecule, cell/gene and biological therapeutics.

More information on: <http://www.LeadsToDevelopment.com>